Understanding Tarsons Products’ Valuation Metrics
As of 1 December 2025, Tarsons Products exhibits a price-to-earnings (PE) ratio of 59.3, signalling a premium valuation relative to earnings. This is considerably higher than many of its peers, although some competitors in the healthcare services space command even loftier multiples. The price-to-book (P/B) ratio stands at 1.94, suggesting the stock trades nearly twice its book value, which is moderate but still indicative of investor confidence in the company’s asset utilisation.
Enterprise value (EV) multiples further illustrate the valuation landscape. The EV to EBIT ratio is notably elevated at 40.7, while EV to EBITDA is 13.3, reflecting expectations of strong operational cash flow generation despite modest profita...
Read More













